The importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.
As part of a transformation to one of the pioneering eye banks in the country, Tissue Banks International (TBI) recently underwent a formal rebranding, changing its name to KeraLink International. This move included shedding the musculoskeletal portion of operations to concentrate on dramatically increasing the number of sight-saving procedures performed globally, explained Douglas Furlong, KeraLink’s president and chief executive officer.
Mooren’s ulcers completely healed in 5 patients treated with rituximab after conventional treatment failed, according to researchers.
Lifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
Recombinant human lubricin showed potential as a new therapeutic approach to the management of dry eye disease in a small clinical trial. Compared with sodium hyaluronate, lubricin (Lubris BioPharma), significantly improved both signs and symptoms of moderate dry eye after two weeks of treatment.
Seasonal and perennial allergic conjunctivitis are common conditions that are not always well-controlled with conventional therapy. Alternative approaches and novel investigational treatments are discussed.
Chronic dry eye disease (DED) affects more than 25 million people and to date the only pharmacologic therapies are topical or involve punctal plugs. Results from two studies wth a neurostimulator indicate there may be a new pathway to upregulate the body’s tear system.
Poor regeneration of the epithelial basement accounts for most 'late haze' associated with PRK, LASIK, infections, or corneal transplants. Proper excimer laser maintenance may reduce irregularities.
Patient symptoms are not an effective method to diagnose dry eye, as they often overlap with other pathologies. Tear osmolarity results provide clues for alternative diagnoses.
A phase I/II trial enrolling patients with Sjögrens syndrome dry eye will be investigating a synthetic fragment of a naturally occurring tear glycoprotein. Findings from extensive laboratory and preclinical research suggest that it is a promising novel therapy.